Multi-omics integration identifies macrophage senescence driven by the RUNX1-P53 axis as a key mechanism in diabetic foot ulcer.
Identifying macrophage aging as a driver of diabetic foot ulcers suggests new targets—senolytic or epigenetic drugs—to break the non-healing cycle.
Diabetic foot ulcers affect ~15-25% of people with diabetes and carry high amputation risk due to chronic non-healing. This multi-omics study identifies macrophage senescence regulated by the RUNX1-P53 axis as a key pathological driver of wound chronicity, offering a mechanistic rationale for senolytic or epigenetic interventions.
What the study was
- Study design
- retrospective_cohort
- Population
- Diabetic foot ulcer patients (human transcriptomics + in vitro validation)
- Category
- Other
- Maturity
- Exploratory
- Journal
- Funct Integr Genomics
Why it surfaced
Standard: aging/senescence mechanism in a high-burden complication of diabetes; multi-omics approach adds molecular depth; limited by bioinformatics-heavy design without clinical intervention; relevant to aging and longevity watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.